Stock EPRSQ EPIRUS BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News EPIRUS Biopharmaceuticals, Inc.

Equities

EPRSQ

US29428P1075

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for EPIRUS Biopharmaceuticals, Inc. -.--% -.--%
2018 Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc. CI
2018 Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q). CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
CI
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).
CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
CI
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.
CI
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.
CI
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index
CI
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index
CI
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations
CI
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy
CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination
CI
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..
CI
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.
CI
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes
CI
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
CI
Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015
CI
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)
CI
Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EPRSQ Stock
  4. News EPIRUS Biopharmaceuticals, Inc.